BANK VONTOBEL/CALL/GILEAD SCIENCES/92/0.1/21.06.24

BANK VONTOBEL/CALL/GILEAD SCIENCES/92/0.1/21.06.24 Stock

Warrant

WGIB2V

CH1260769364

Market Closed - Swiss Exchange 11:20:00 2024-05-29 EDT
0.04 ^CHF	-2.44%

6 months	-48.72%
Current year	-72.60%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart GILEAD SCIENCES, INC.

Chart BANK VONTOBEL/CALL/GILEAD SCIENCES/92/0.1/21.06.24

Latest news about GILEAD SCIENCES, INC.

Health Care Slips as Gilead Rallies on Weight-Loss Plans - Health Care Roundup	06-14	DJ
EU regulator mandates label updates on CAR-T cancer therapies	06-14	RE
Gilead Sciences' Kite Unit Reports Positive Data From New Analyses of Yescarta	06-14	MT
New Kite Clinical Research and Real-World Evidence for Yescarta® Demonstrate Benefit From Earlier Lines of Treatment	06-14	BU

More news

Static data

Product type	Plain-Vanilla-Warrants
Buy / Sell	CALL
Underlying	GILEAD SCIENCES, INC.
Issuer	Vontobel
	WGIB2V
ISIN	CH1260769364
Date issued	2023-05-05
Strike	92 $
Maturity	2024-06-21 (6 Days)
Parity	10 : 1
Emission price	0.37 CHF
Emission volume	N/A
Settlement	physical
Currency	CHF

Technical Indicators

Highest since issue	0.425 CHF
Lowest since issue	0.04 CHF
Spread	0.038 CHF
Spread %	95.00%

Company Profile

Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).

Sector

More about the company